Skip to main content
. 2022 Sep 9;101(36):e30170. doi: 10.1097/MD.0000000000030170

Table 1.

Intervention characteristics of included studies.

Study/ID Hospitalization time Type Histological type (observation/control) Clinical stage N (observation/control) Regimen
Squamous Adeno Adenosquamous Observation Control
Lu et al[16] 2017.01–2020.01 RCT 66/32 12/6 0 IB2–IVA 78/38 E + CCRT (cisplatin, qw) CCRT (cisplatin, qw)
Chen and Fu[17] 2016.02–2018.02 NRCT 49/46 11/10 0 IIB–IVA 60/56 E + CCRT (TP) CCRT(TP)
Dili et al[18] 2015.01–2017.05 Cohort study 54/58 24/28 0 IIB–IVA 78/86 E + CCRT (DDP, qw) CCRT (DDP, qw)
Tang[19] 2017.07–2018.11 NRCT 27/27 3/3 0 IIB–IVA 30/30 E + CCRT (DDP, qw) CCRT (DDP, qw)
Xu et al[20] 2014.02–2016.05 RCT 26/28 6/6 0 IIB–IVA 32/34 E + CCRT (DDP, qw) + thermotherapy CCRT (DDP, qw) + thermotherapy
Fan et al[21] 2013.02–2014.02 RCT 20/21 8/7 0 IIB–IVA 28/28 E + CCRT (DDP, qw) CCRT (DDP, qw)
Luo[22] 2011.01–2014.01 RCT 20/22 13/11 0 IIB–IVA 33/33 E + CCRT (liposome, qw) CCRT (liposome, qw)
Liu et al[23] 2007.01–2008.12 NRCT 25/25 0 0 III bulky 25/25 E + CCRT (DDP, qw) + SC (TP) CCRT (DDP, qw) + SC (TP)
Ke et al[24] 2009.10–2010.1 RCT 18/19 8/7 0 IIB–IVA 26/26 E + CCRT (DDP, qw) CCRT (DDP, qw)
Shu et al[15] 2019.06–2020.12 RCT 48/43 0 0 IB3–IVA 48/43 E + CCRT (TP) CCRT (TP)
Zhao et al[25] Unknown RCT 15/15 5/5 5/5 IIB–IV 25/25 E + CCRT (DDP qw + Hu po bid) CC (DDP qw + Hu po bid)
Zhang[26] 2010.2–2013.6 Cohort study 49/40 8/6 0 IIB–IVA 57/46 E + CCRT (DDP, qw) CC (DDP, qw)
Li[27] 2017.1–2020.2 NRCT 28/27 8/7 0 IIB–IIIB 36/34 E + CCRT (DDP, qw) CC (DDP, qw)

CCRT = concurrent chemoradiotherapy, DDP = cisplatin, E + CCRT = endostar + concurrent chemoradiotherapy, NRCT = nonrandomized controlled trial, RCT = randomized controlled trial, TP = triptolide.